Literature DB >> 314270

Emergence of resistance to cefamandole: possible role of cefoxitin-inducible beta-lactamases.

C C Sanders, W E Sanders.   

Abstract

Selection of resistance to cefamandole has been observed, and the drug has failed to protect animals lethally infected with certain Enterobacteriaceae that appeared to be highly susceptible in vitro. Using spectrophotometric assays, some of these organisms were found to produce beta-lactamases highly active against cefamandole. Cefoxitin, a poor enzyme substrate, was found to be superior to both cephalothin and cefamandole in induction of these enzymes. A simple disk induction test was developed and used to examine 147 Enterobacteriaceae for production of these beta-lactamases. The enzymes were found in 69% of cephalothin-resistant, cefamandole-susceptible strains and in only 3% of strains susceptible to both cephalothin and cefamandole. They were most prevalent among isolates of Enterobacter, indole-positive Proteus, and Serratia. Since selection of resistance and therapeutic failures have occurred most often among these genera, the relationship between presence of inducible enzymes and outcome of therapy should be examined further in humans.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 314270      PMCID: PMC352760          DOI: 10.1128/AAC.15.6.792

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  23 in total

1.  Comparison of BL-S786 with cephalothin, cefamandole and cefoxitin in vitro and in treatment of experimental infections in mice.

Authors:  R V Goering; C C Sanders; W Sanders
Journal:  J Antibiot (Tokyo)       Date:  1978-04       Impact factor: 2.649

Review 2.  Factors influencing the antibacterial action of beta-lactam antibiotics.

Authors:  M H Richmond
Journal:  J Antimicrob Chemother       Date:  1978-07       Impact factor: 5.790

Review 3.  Cefoxitin, a semi-synthetic cephamycin: a microbiological overview.

Authors:  J Birnbaum; E O Stapley; A K Miller; H Wallick; D Hendlin; H B Woodruff
Journal:  J Antimicrob Chemother       Date:  1978-07       Impact factor: 5.790

4.  Cefamandole nafate therapy of respiratory tract, skin, and soft tissue infections in 74 patients.

Authors:  R L Perkins; R J Fass; J F Warner; R B Prior; T M File; R R Tight; W G Gardner; D E Ruiz; T G Slama
Journal:  J Infect Dis       Date:  1978-05       Impact factor: 5.226

5.  Cefoxitin, a semisynthetic cephamycin antibiotic: antibacterial spectrum and resistance to hydrolysis by gram-negative beta-lactamases.

Authors:  H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1974-08       Impact factor: 5.191

6.  Cefamandole, a cephalosporin antibiotic with an unusually wide spectrum of activity.

Authors:  H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1974-08       Impact factor: 5.191

7.  Use of cefoxitin, new cephalosporin-like antibiotic, in the treatment of aerobic and anaerobic infections.

Authors:  S R Nair; C E Cherubin
Journal:  Antimicrob Agents Chemother       Date:  1978-12       Impact factor: 5.191

8.  Cefamandole--a status report based on the symposium on cefamandole.

Authors:  R C Moellering
Journal:  J Infect Dis       Date:  1978-05       Impact factor: 5.226

9.  A comparative study of the activity of cefamandole and other cephalosporins and analysis of the beta-lactamase stability and synergy of cefamandole with aminoglycosides.

Authors:  K P Fu; H C Neu
Journal:  J Infect Dis       Date:  1978-05       Impact factor: 5.226

10.  Cefamandole---a review of chemistry and microbiology.

Authors:  G V Kaiser; M Gorman; J A Webber
Journal:  J Infect Dis       Date:  1978-05       Impact factor: 5.226

View more
  76 in total

1.  ampR gene mutations that greatly increase class C beta-lactamase activity in Enterobacter cloacae.

Authors:  A Kuga; R Okamoto; M Inoue
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

2.  Occurrence of newer beta-lactamases in Klebsiella pneumoniae isolates from 24 U.S. hospitals.

Authors:  Ellen Smith Moland; Jennifer A Black; Jason Ourada; Mark D Reisbig; Nancy D Hanson; Kenneth S Thomson
Journal:  Antimicrob Agents Chemother       Date:  2002-12       Impact factor: 5.191

3.  A pleiotropic, posttherapy, enoxacin-resistant mutant of Pseudomonas aeruginosa.

Authors:  L J Piddock; M C Hall; F Bellido; M Bains; R E Hancock
Journal:  Antimicrob Agents Chemother       Date:  1992-05       Impact factor: 5.191

4.  AmpC disk test for detection of plasmid-mediated AmpC beta-lactamases in Enterobacteriaceae lacking chromosomal AmpC beta-lactamases.

Authors:  Jennifer A Black; Ellen Smith Moland; Kenneth S Thomson
Journal:  J Clin Microbiol       Date:  2005-07       Impact factor: 5.948

5.  Emergence of resistance to beta-lactam agents in Pseudomonas aeruginosa with group I beta-lactamases in Spain.

Authors:  K Colom; A Fdz-Aranguiz; E Suinaga; R Cisterna
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-11       Impact factor: 3.267

6.  Model system to evaluate the effect of ampD mutations on AmpC-mediated beta-lactam resistance.

Authors:  Amber J Schmidtke; Nancy D Hanson
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

Review 7.  Extended-spectrum-beta-lactamase, AmpC, and Carbapenemase issues.

Authors:  Kenneth S Thomson
Journal:  J Clin Microbiol       Date:  2010-02-24       Impact factor: 5.948

8.  Antibiotic resistance: a local hospital or community problem.

Authors:  T M File; M T Haug; R B Thomson; J S Tan; S J Salstrom; L Tan; V Osborne; C Stephens
Journal:  Bull N Y Acad Med       Date:  1987-04

9.  Comparison of ceftazidime with cefamandole for therapy of community-acquired pneumonia.

Authors:  J C Engle; P W Lifland; C J Schleupner
Journal:  Antimicrob Agents Chemother       Date:  1985-07       Impact factor: 5.191

10.  What do beta-lactamases mean for clinical efficacy?

Authors:  H C Neu
Journal:  Infection       Date:  1983       Impact factor: 3.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.